Mutations in the NF1 gene cause NF1, a genetic disorder with an incidence of 1/3,500 live births worldwide. This condition is characterized by malignant and nonmalignant pathologies, including skeletal manifestations [1] [2] [3] [4] [5] [6] . Dystrophic scoliosis, tibia bowing, bone fragility, fracture and pseudarthrosis (nonunion following fracture) are skeletal conditions associated with high morbidity in this population [7] [8] [9] [10] . Despite recent progress toward understanding the role of NF1 in skeletal tissues, it is still unclear why and how these bone pathologies arise, raising uncertainty regarding optimal treatment 2,3 .
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Although individuals with NF1 are typically born with heterozygous mutations in NF1, loss of heterozygosity has been detected in pseudarthrosis biopsies 11 , suggesting that local somatic NF1 loss of function contributes to NF1 skeletal dysplasia. This point is further supported by the relative commonality of defects observed between pseudarthrosis lesions from individuals with NF1 and the skeleton of mice characterized by conditional loss of Nf1 in osteoprogenitors. These mice indeed tend to recapitulate, in their entire skeleton, the genetic and cellular consequences of NF1 loss of function that occurs locally in human NF1 pseudarthroses. Nf1 inactivation in osteochondroprogenitors in Nf1 flox/flox ; Prx-cre or Nf1 flox/flox ; Col2a1-cre mice (herein called Prx-Nf1 KO or Col2-Nf1 KO mice, respectively) led to reduced stature, low bone mass, tibia bowing, diaphyseal ectopic blood vessel formation and hypomineralization associated with weakened bone mechanical properties. Bone cellular parameters also indicated that neurofibromin is required for normal osteoblast differentiation and expression of Tnfsf11, the gene encoding receptor activator of nuclear factor κB ligand, and hence for osteoclastogenesis [12] [13] [14] [15] [16] [17] [18] . The existence of Nf1-deficient osteoblasts in an Nf1 heterozygous bone microenvironment has also been shown to cause bone loss and delayed bone healing in Nf1 flox/flox ; Col1a1-cre (Col1-Nf1 KO) mice via activation of transforming growth factor-β (TGF-β) signaling 19 . Notably, each of these NF1 models, as well as bone biopsies from individuals with NF1 pseudarthrosis 20 , are characterized by excessive deposition of unmineralized bone matrix (osteoid) despite normal serum phosphate and calcium concentrations.
Bone matrix mineralization is a tightly regulated process that requires collagen, calcium and phosphate to form ordered crystals of hydroxyapatite, as well as tissue-nonspecific alkaline phosphatase (ALP) activity to hydrolyze PP i (a potent inhibitor of mineralization) and generate inorganic phosphate 21 . Extracellular concentrations of PP i are determined by (i) its degradation via ALP, (ii) its synthesis catalyzed by the nucleoside triphosphate pyrophosphohydrolase ENPP1/PC-1 (called ENPP1 herein) and (iii) its transport into the extracellular milieu through the PP i channel ANK 22 . Mineralization is also controlled by Phospho1, a phosphatase that provides intracellular inorganic phosphate to generate PP i 23 , and by glycoproteins such as osteopontin, which inhibits crystal nucleation on collagen fibers in mineralizing vesicles 24, 25 . Multiple growth factors such as TGF-β, activin A, bone morphogenic protein-2 (BMP2), insulin-like growth factor-1, fibroblast growth factor-2 and fibroblast growth factor-23 are involved in bone and/or cartilage mineralization [26] [27] [28] [29] [30] [31] [32] [33] [34] . A common signaling pathway engaged by these factors is the RAS-ERK pathway, which is constitutively activated in cells lacking neurofibromin, the RAS GTPase-activating protein (RAS-GAP) encoded by NF1 (ref. 35) . We thus hypothesized that neurofibromin, via its inhibitory action on RAS-ERK signaling in bone-forming cells, could be an important regulator of bone matrix mineralization and bone mechanical properties. We show here that neurofibromin inhibits the expression of genes increasing PP i extracellular levels and that hydrolysis of excess PPi with a recombinant form of ALP improves bone growth and mineralization in mouse models of NF1 skeletal dysplasia. These data suggest a potential pharmacological avenue to prevent some of the skeletal abnormalities of individuals with NF1.
RESULTS

Uncontrolled PP i production in Nf1-deficient bone cells
To address whether and how Nf1 regulates bone mineralization, we first asked whether Nf1 ablation in bone marrow stromal cells (BMSCs) affects extracellular PP i concentrations. BMSCs from Col2-Nf1 KO mice, lacking Nf1 in osteochondroprogenitor cells, showed a 60-70% lower Nf1 expression compared to those from wild-type (WT) mice (Fig. 1a) , consistent with the heterogeneous nature of the cell populations that comprise BMSC cultures 36 . This lower Nf1 expression level was accompanied by a significantly higher (70%) extracellular PP i concentration in the conditioned medium of undifferentiated BMSC cultures compared to that of WT controls (Fig. 1b) . Addition of a recombinant form of ALP, in the form of sALP-FcD10 (also known as asfotase-α, 0.5 µg ml −1 ) to induce PP i hydrolysis significantly reduced the amount of PP i detected in both genotypes, confirming the validity of the PP i measurements.
High extracellular PP i concentration can be generated by increased production of PP i by the ectonucleophosphatase ENPP1 and by increased cellular export through the transporter ANK. Both Ank and Enpp1 mRNA (Fig. 1c) and protein (Supplementary Fig. 1a ) levels were higher in Nf1-deficient BMSCs compared to WT BMSCs. Expression of the gene encoding osteopontin (Spp1) was also higher in Nf1-deficient BMSCs (Fig. 1c) , consistent with the reported stimulatory effect of PP i on Spp1 expression 25 . We obtained similar results when comparing Nf1-deficient osteoprogenitor cells generated from Nf1 flox/flox BMSC cultures infected with a Cre-expressing adenovirus to control Nf1 flox/flox BMSC cultures infected with a GFP-expressing adenovirus (Supplementary Fig. 1b) , which confirmed that the changes in gene expression measured in BMSCs from Col2-Nf1 KO mice were not caused by fewer osteoprogenitors initially plated. Ank, Enpp1 and Spp1 expression was also significantly higher in long bones, calvarias and epiphyses (cartilage) from 3-week-old Col2-Nf1 KO versus WT mice (Fig. 1d) , whereas expression of Runx2 and Alpl, two osteoblast differentiation marker genes, was lower ( Supplementary Fig. 1c) . Lastly, MEK inhibition by U0126 (1 µM, 24 h) blunted the increase in Ank, Enpp1 and Spp1 expression observed in Nf1-deficient BMSCs, indicating that neurofibrin controls the expression of these genes in a RAS/ERK-dependent fashion ( Fig. 1c and Supplementary Fig. 1b) .
To assess whether these molecular findings in mice could be replicated in humans, we obtained RNA from adherent human bone stromal cells prepared from bone biopsies from six healthy control subjects without NF1 and nine individuals with NF1 tibial pseudarthrosis, and measured ENPP1 and ANKH transcript levels by quantitative PCR. Consistent with the mouse data, ENPP1 expression was significantly higher in cultured cells from NF1 pseudarthrosis tissues (Fig. 1e) , despite the small number of available samples and consistent with the cell heterogeneity of these cultures. ANKH expression, however, was variable between samples and not significantly different between cultures from normal and NF1 pseudarthrosis biopsies (Fig. 1f) .
Mice lacking Nf1 in mature osteoblasts (Col1-Nf1 KO mice) have a uniform distribution of nonmineralized matrix throughout trabecular bone compartments 18 , whereas mice lacking Nf1 in osteochondroprogenitors and chondrocytes (Col2-Nf1 KO mice) are characterized by an osteoid preferentially distributed in the primary spongiosa, where osteoblasts and chondrocytes mineralize their matrix (Fig. 2a) . On the basis of these observations and because neurofibromin is expressed in hypertrophic chondrocytes 37, 38 , we hypothesized that this RAS-GAP could also contribute to cartilage mineralization, which is a process important for bone growth and ossification during development and bone healing in adults. In support of this hypothesis, Col2-Nf1 KO chondrocyte high-density micromass cultures generated a typical Alcian blue-positive matrix but did not show signs of mineralization, in contrast to WT chondrocyte cultures (Fig. 2b) . In addition, Ank, Enpp1 and Spp1 expression was significantly higher in Nf1-deficient micromass chondrocyte cultures versus WT cultures (Fig. 2c) , in agreement with the data obtained from cartilaginous epiphyses, which contain a high proportion of chondrocytes (Fig. 1d) . Accordingly, extracellular PP i concentration ( Fig. 2d) and Enpp1 enzymatic activity ( Fig. 2e) were significantly higher, whereas ALP activity was lower ( Fig. 2f) in Nf1-deficient versus WT chondrocytes.
Lack of Nf1 in BMSCs impairs BMP2 osteogenic action
BMSCs isolated from Col2-Nf1 KO mice displayed, compared to BMSCs isolated from WT mice, a significantly lower differentiation potential, as determined by lower osteoblast colony-forming unit (CFU-Ob) number, lower tissue-nonspecific ALP activity ( Fig. 3a) and lower expression of osteoblast differentiation markers including Runx2, Alpl and Bglap, the gene encoding osteocalcin (Fig. 3b) . We obtained similar results using Nf1 flox/flox BMSCs infected with a Cre-expressing adenovirus ( Supplementary Fig. 1d,e) . However, in contrast to what we observed in the case of Ank and Enpp1 expression, MEK inhibition by U0126 (1 µM), tremetinib or PD198306 (0.1 µM and 200 nM, respectively, data not shown) for 24 h did not correct the expression level of Runx2 or Alpl in Nf1-deficient BMSCs (Fig. 3c) , indicating that the expression of these two genes is not directly controlled by neurofibromin. Extracellular PP i concentration, as well as Ank, Enpp1 and Spp1 expression, remained above or equal to that of WT controls throughout the differentiation period (Fig. 3d,e) .
BMPs are known for their ability to promote osteoprogenitor differentiation 39 but have had limited effects on the differentiation of Nf1-heterozygous osteoprogenitors and on bone union in Nf1-heterozygous mice 40, 41 . Recombinant human BMP2 (100 ng ml −1 ) did not stimulate ALP activity or CFU-Ob formation in BMSC cultures from Col2-Nf1 KO mice, although it did, as expected, promote CFU-Ob formation and ALP activity in WT BMSC cultures following 2 weeks of treatment (Fig. 4a) . Smad1 and Smad5 phosphorylation in response to BMP2 treatment (100 ng ml −1 , 1 h) was not affected by Nf1 deficiency (Fig. 4b) , indicating that the lack of stimulatory effect of BMP2 on Nf1-deficient BMSC differentiation is not caused by repression of BMP2 receptor expression or by the production of factors inhibiting canonical Smad signaling. Treatment with BMP2 for 2 weeks also failed to increase the expression of Alpl, Runx2 and Col1a1 in BMSC cultures from Col2-Nf1 KO mice (Fig. 4c) . However, it significantly increased the expression of Ank and Enpp1 (but not Spp1) (Fig. 4d) and PP i extracellular concentration (Fig. 4e) in both WT and Nf1-deficient BMSCs. CFU-Ob formation, ALP activity (Fig. 4f,g ) and the expression of Alpl and Col1a1 ( Supplementary  Fig. 2a,b) in Nf1-deficient BMSC cultures were higher following a 2-week-long combined treatment with the MEK inhibitor U0126 (1 µM) and BMP2 (100 ng ml −1 ), but not with either of these treatments alone. This combination treatment also partially reduced the increased Ank and Enpp1 expression and PP i extracellular concentration detected in vehicle-treated Nf1-deficient BMSC cultures, possibly owing to the antagonistic effect of these two drugs on Ank and Enpp1 expression ( Supplementary Fig. 2c,d ).
sALP-FcD10 improves bone growth and mineral density in Col2-Nf1 KO mice If excessive extracellular PP i levels cause the mineralization deficit observed in Col2-Nf1 KO mice, then reducing PP i concentration should have beneficial effects on matrix mineralization. This is experimentally possible by inhibiting PP i generation or increasing its catabolism. We chose the latter approach because PP i is a substrate for ALP, and a recombinant form of human ALP is clinically available to treat ALPL-deficient subjects with hypophosphatasia 42, 43 . We thus treated WT and Nf1-deficient BMSCs with vehicle or sALP-FcD10 (0.5 mg ml −1 ) in osteogenic conditions for 14 d and assessed matrix mineralization. As predicted, sALP-FcD10 increased matrix mineralization in both genotypes, although the relative increase was more pronounced in cultures from Col2-Nf1 KO than in those from WT mice (Fig. 5a ). This pronounced increase occurred despite the persistent differentiation deficit of Nf1-deficient BMSCs in the presence of sALP-FcD10 (Supplementary Fig. 3a) . Treatment with sALP-FcD10 reduced Spp1 expression in Nf1-deficient BMSCs ( Supplementary  Fig. 3a ), in agreement with the known stimulatory effect of PP i on Spp1 expression 25 . On the basis of these encouraging results, we treated Col2-Nf1 KO newborn mice daily with subcutaneous injections of sALP-FcD10 (8.2 mg per kg body weight per d) for 18 d 44, 45 . Col2-Nf1 KO mice have short stature, low bone mass, decreased bone mineralization, cortical thickness and mineral density, and high cortical porosity 37 . Following this short treatment (dictated by the relatively high death rate of these mice at weaning), we observed a significant 73% increase in the size of mutant mice (Fig. 5b) and a clear increase in vertebral and tibial bone mineral density on radiographs (Fig. 5c,d) . Treatment with sALPFcD10 also significantly increased mid-diaphyseal cortical bone thickness, as measured by three-dimensional microcomputed tomography (µCT) (Fig. 5e) , partially rescued the formation of secondary ossification centers, expanded tibia metaphyseal envelopes and increased the amount of calcified matrix in the growth plate hypertrophic zone of Col2-Nf1 KO mice (Fig. 5f) . Despite the seemingly pronounced effects of sALP-FcD10 observed by radiography and µCT, tibia cortical tissue mineral density and mineral-to-collagen ratio ( Supplementary  Fig. 3b,c) were not increased following treatment.
sALP-FcD10 increases bone mineralization in Osx-Nf1 KO mice
Because Col2-Nf1 KO mice manifest severe developmental phenotypes that limit their survival and thus the duration of treatments, we generated mice in which Nf1 can be ablated postnatally in osteoprogenitors expressing Sp7 (also known as Osx) by crossing the inducible Tet-Off-based Osx-cre transgenic mice 46 with Nf1 flox/flox mice 47 . This new mouse model makes it possible to dissect the mechanisms by which postnatal Nf1 ablation impairs bone homeostasis, without complications arising from developmental phenotypes. Osx-cre; Nf1 Osx flox/flox mice (herein called Osx-Nf1 KO mice) were undistinguishable in size from WT littermates upon doxycycline administration (i.e., Cre recombinase repression) from conception to day 14 ( Fig. 6a) and had normal phosphate, calcium and 25-hydroxycholecalciferol (vitamin D) serum concentrations (Supplementary Table 1 ). Osx-cre-mediated Nf1 ablation in osteoprogenitors at postnatal day 14 following doxycycline withdrawal, as seen in Col2-Nf1 KO mice, caused hyperosteoidosis (Fig. 6b) , lower bone mass (Fig. 6c) , higher femoral diaphyseal cortical porosity (Fig. 6d) and lower cortical thickness, midshaft moment of inertia and cortical tissue mineral density compared to WT mice (Fig. 6e-g ). Cortical mineral-to-collagen ratio measured by Raman spectroscopy (Fig. 6h) c WT, n = 14, KO + vehicle, n = 8, KO + sALP-FcD10, n = 13; P value determined by one-way ANOVA), vertebral (c, scale bar, 250 µm; WT, n = 14, KO + vehicle, n = 8, KO + sALP-FcD10, n = 13; P value determined by one-way ANOVA) and tibial (d, scale bar, 250 µm; WT, n = 14, KO + vehicle, n = 8, KO + sALP-FcD10, n = 13; P value determined by one-way ANOVA), bone mineral density (X-rays), cortical thickness (e, Ct.Th, µCT; WT, n = 16, KO + vehicle, n = 8, KO + sALP-FcD10, n = 13; P value determined by one-way ANOVA with Holm-Sidak's method), epiphyseal diameter (f, white arrows; scale bar, 45 µm; µCT) and hypertrophic zone von Kossa-positive calcified bone volume/tissue volume (hBV/TV, histology; WT, n = 7, KO + vehicle, n = 6, KO + sALP-FcD10, n = 7; P value determined by one-way ANOVA) in Col2-Nf1 KO newborn pups treated daily with sALP-FcD10 for 18 d. *P < 0.05 versus WT; # P < 0.05 versus vehicle in the same genotype group. Data are expressed as mean ± s.d. was also lower in Osx-Nf1 KO mice, and femurs from Osx-Nf1 KO mice were mechanically weaker than those from WT controls, as measured by three-point bending tests (Supplementary Table 2) .
Col2
To assess the effect of sALP-FcD10 on the skeleton of this mouse model, we administered sALP-FcD10 daily from 2 weeks of age (at the time of Nf1 ablation) for 6 weeks. In Osx-Nf1 KO mice, treatment with sALP-FcD10 significantly increased trabecular bone volume/tissue volume ratio and moment of inertia, as assessed by µCT (Fig. 6c,f) , as well as femoral stiffness, modulus and peak force, as measured by three-point bending (Supplementary Table 2) , and led to a nonsignificant trend for increased cortical femoral thickness (Fig. 6e) . Treatment with sALP-FcD10 also improved bone mineralization in Osx-Nf1 KO mice, as measured by a drastic 73% reduction in osteoid volume per bone volume, a 65% reduction in osteoid surface per bone surface, a 53% decrease in osteoid thickness (Fig. 6b) and a 20% increase in mineral-to-collagen ratio (Fig. 6h) .
DISCUSSION
We show here that the RAS-GAP activity of neurofibromin in the bone mesenchymal lineage restrains the expression of Enpp1 and Ank, two main genes controlling PP i homeostasis, and that increasing PP i catabolism through enzyme therapy considerably improves bone mineralization and bone mechanical properties in mouse models of NF1 skeletal dysplasia. These results, along with suggestive evidence of conservation of function between mice and humans, support the causal role of increased PP i levels in the etiology of NF1-related hyperosteoidosis and position neurofibromin as a critical and obligatory regulator of cartilage and bone mineralization. They also provide preclinical evidence that some of the most clinically challenging NF1-related skeletal maladies might be preventable.
Hyperactive TGF-β signaling has been proposed to cause bone loss and to delay bone healing in mice deficient for Nf1 in mature osteoblasts and heterozygous for Nf1 (ref. 19) . TGF-β is also known to stimulate ERK activity and Ank and Enpp1 expression, and to increase PP i concentration in WT chondrocytes 48, 49 . Therefore, NF1-deficient BMSCs may contribute cell autonomously and/or in a hyperactive TGF-β paracrine fashion to the extraphysiological skeletal accumulation of PP i and to the impaired osteoblast differentiation and matrix mineralization observed in the setting of NF1. The beneficial effect of sALP-FcD10 on bone growth, mineralization and strength observed in this study suggests that PP i accumulation and abnormal mineralization are important components of NF1-related bone dysplasia. However, further studies will be necessary to determine the evolution and contribution of all the cellular defects typical of Nf1-deficient bone cells on bone mass and strength over extended periods of treatment with sALP-FcD10, as this drug does not correct the differentiation phenotype of Nf1-deficient osteoblasts. Although TGF-β blockade might theoretically be used to promote bone union in children with NF1 pseudarthrosis, the cancer-prone status of this pediatric population and the known tumor-suppressor activity of TGF-β signaling limit this therapeutic approach 50 . Our results, on the other hand, suggest that stimulation of PP i catabolism through enzyme therapy could be applied on a more chronic basis before fracture to strengthen the NF1-related dysplastic bones and prevent their mechanical failure.
The mineralization deficit of Nf1-deficient BMSCs could be detected in immature BMSCs before their differentiation into osteoblasts. Therefore, this phenotype cannot be attributed to the reduced differentiation potential of Nf1-deficient BMSCs, although the latter certainly contributes to the low bone mass phenotype observed in the two NF1 mouse models used in this study. It is also worth noting that BMP2 treatment, without the need for ERK blockade, stimulated the expression of Ank and Enpp1 and increased extracellular PP i concentration in Nf1-deficient BMSC cultures, as shown previously in WT cells 28 . This observation could explain why recombinant human BMP2 alone did not improve bone healing in NF1 mouse models 40, 41 and bone union in individuals with NF1-related pseudarthrosis [51] [52] [53] .
Our results indicate that Nf1-deficient BMSCs are not responsive to BMP2 with regard to their differentiation potential and suggest that this defect may in part underlie their inability to differentiate. In addition, the response of Nf1-deficient BMSCs to BMP2 with regard to Ank and Enpp1 expression suggests that neurofibromin is not the sole negative regulator of the RAS-ERK signaling pathway upstream of these two genes. These results also indicate that the stimulatory effect of BMP2 on osteoprogenitor differentiation requires controlled ERK signaling by neurofibromin.
It is unknown to what extent poor matrix mineralization contributes to the low bone mineral density, tibia bowing, poor mechanical properties and possibly pseudarthrosis observed in children with NF1. Although local PP i concentration could not be quantified, the observed increase in the expression of ENPP1 in BMSCs extracted from biopsies of pseudarthroses from patients with NF1, as well as the presence of thick osteoid seams on histological sections 20 , supports conservation of function between mice and humans.
Pseudarthrosis and dystrophic scoliosis can currently be treated only by invasive, and often repetitive, surgical orthopedic interventions 2, 3 . Most approaches to date are corrective in nature, and only bracing techniques are available to reduce the incidence and severity of these complications. Of major interest is the possibility that sALP-FcD10, if applied preventatively, might improve mineralization, growth, architecture and mechanical properties of dysplastic bones affected by NF1 and, thus, limit their likelihood of deformation and fracture. This latter point is particularly noteworthy, as the current standard for treatment is limited to avoidance of prophylactic surgery and early long-term bracing to prevent fracture until skeletal maturity is reached. It is worth emphasizing that sALP-FcD10 targets bone and is already successfully used in the clinic to treat children with hypophosphatasia 42 . Therefore, its potential use in the context of NF1-related skeletal dysplasia has an advantage over the development of other experimental drugs that target this and other aspects of the NF1 skeletal pathologies.
METhODS
Methods and any associated references are available in the online version of the paper. 
